Therefore, in this study, we aimed to conduct a retrospective cohort study to investigate the therapeutic outcomes of diverse EGFR TKIs in patients with metastatic NSCLC harboring p.L747P mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.